SABCS 2022: Destiny Breast-02, Destiny Breast-03 & TRIO-U…

SABCS 2022 Day 2 Press Conference December 7, 2022. Ian E. Krop, MD, PhD from Yale University discusses Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized phase 3 study DESTINY-Breast02Sara Hurvitz, MD from UCLA Health discusses Trastuzumab deruxtecan…

Read the full article here

Related Articles